Table 1.
Clinical Characteristics of Studied Patients
Group A | Group B | Group C | Group D | P | |
---|---|---|---|---|---|
No. | 40 | 34 | 42 | 15 | |
Age, y | 70.4 ± 8.1 | 67.4 ± 10.6 | 70.1 ± 9.9 | 74.5 ± 8.6 | 0.1222 |
Sex (male) | 25 (62.5%) | 23 (67.6%) | 27 (64.3%) | 11 (73.3%) | 0.8818 |
Risk factor | |||||
HT | 24 (60.0%) | 25 (73.5%) | 32 (76.2%) | 14 (93.3%) | 0.0586 |
HL | 32 (80.0%) | 26 (76.5%) | 17 (40.5%) | 7 (46.7%) | 0.0003 |
DM | 16 (40.0%) | 15 (44.1%) | 11 (26.2%) | 5 (33.3%) | 0.3752 |
Laboratory data | |||||
TG | 171.0 ± 121.8 | 175.0 ± 141.5 | 151.9 ± 73.0 | 143.4 ± 78.1 | 0.7044 |
HDL‐C | 49.9 ± 13.8 | 47.4 ± 12.7 | 48.9 ± 11.6 | 51.3 ± 12.8 | 0.7713 |
LDL‐C | 112.9 ± 33.1 | 132.2 ± 41.1 | 107.0 ± 27.6 | 121.4 ± 24.8 | 0.1593 |
TC | 189.5 ± 39.0 | 196.6 ± 39.4 | 182.5 ± 21.6 | 189.8 ± 22.8 | 0.4948 |
BS | 121.2 ± 33.8 | 143.8 ± 52.9 | 125.4 ± 41.1 | 132.9 ± 37.8 | 0.1427 |
HbA1c | 6.2 ± 1.5 | 6.1 ± 1.2 | 5.7 ± 0.9 | 5.8 ± 1.0 | 0.3767 |
Medication | |||||
Aspirin | 35 (87.5%) | 31 (91.2%) | 19 (45.2%) | 3 (20.0%) | <0.0001 |
Statin | 25 (62.5%) | 19 (55.9%) | 12 (28.6%) | 2 (13.3%) | 0.0008 |
ACEI/ARB | 10 (25.0%) | 18 (52.9%) | 15 (35.7%) | 10 (66.7%) | 0.0082 |
CCB | 13 (32.5%) | 12 (35.3%) | 14 (33.3%) | 7 (46.7%) | 0.7323 |
BB | 11 (27.5%) | 8 (23.5%) | 7 (16.7%) | 1 (6.7%) | 0.3711 |
Lesion location | |||||
LAD | 22 (55.0%) | 22 (64.7%) | 22 (52.4%) | 10 (66.7%) | |
RCA | 11 (27.5%) | 8 (23.5%) | 14 (33.3%) | 4 (26.7%) | |
LCX | 7 (17.5%) | 4 (11.8%) | 6 (14.3%) | 1 (6.7%) | 0.8701 |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β‐blocker; BS, blood sugar; CCB, calcium channel blocker; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; HL, hyperlipidemia; HT, hypertension; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LDL‐C, low‐density lipoprotein cholesterol; RCA, right coronary artery; TC, total cholesterol; TG; triglyceride.